drugset / Trial / NCT04260360
Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This study evaluates the use of NanoDoce injected directly into tumors in the kidney of people with renal cell carcinoma.
Timeline
- Start
- 2020-04
- Primary completion
- 2022-06
- Completion
- 2022-10
Outcome
Outcome not reported
Stopped: “Not initiated”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 2 mg/ml | Other |
| Subject | Docetaxel | Small molecule | 6 mg/ml | Other |